viewFevertree Drinks PLC

Fevertree shares fizz on bullish update

Shares were up more than 10% this morning following another bullish trading update

Fevertree tonic water
Fevertree sells premium mixers like tonic water and ginger beer

Shares in Fevertree Drinks PLC (LON:FEVR) gained more than 10% in early deals after the premium drinks mixer brand said it expects its full-year results to top market expectations again.

The group – which makes mixers such as tonic, ginger beer and lemonade – had already upped its full-year expectations once this year following a good start to 2016.

This solid performance has continued into the second half of the year, London-based Fevertree said, with demand in the UK - its largest market - showing no sign of slowing.

Because of this, the firm – which was only founded in 2005 – expects its results for the year to 31 December to come in “materially ahead” of current market forecasts.

This time last year, Fevertree relayed a similar message to investors that it would beat full-year expectations, something it repeated again in April of this year.

The stock has gained more than 500% since it listed two years ago today.

Chris Wickham of Whitman Howard expects positive trading announcements to be an "ongoing feature" for the business with market forecasts likley to underestimate future growth in his opinion.

Wickham reckons the stock has a little more room for growth, too, upping his price target for Fevertree to 1,080p from 720p. 

Shares were up 10% to 1,064p in early deals on Monday.

Quick facts: Fevertree Drinks PLC

Price: 2113 GBX

Market: AIM
Market Cap: £2.45 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Futura Medical sees 'potentially quicker route to market' for its erectile...

Futura Medical PLC's (LON:FUM) executive director and head of R&D Ken James speaks to Proactive London's Andrew Scott following the read-out from the phase III clinical trial of its erectile dysfunction gel. James says while MED2005 showed strong efficacy, excellent safety and rapid speed...

1 hour, 35 minutes ago


Director Disclosure

1 week, 5 days ago

Trading Update

3 weeks ago

Director/PDMR Shareholding

3 weeks, 2 days ago

Interim Results

on 23/7/19

2 min read